PMID- 10926788
OWN - NLM
STAT- MEDLINE
DCOM- 20000829
LR  - 20061115
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 78
IP  - 2
DP  - 2000 Aug
TI  - Expression of matrix metalloproteinases and related tissue inhibitors in the cyst 
      fluids of ovarian mucinous neoplasms.
PG  - 106-12
AB  - OBJECTIVES AND METHODS: The growth of an ovarian cystic neoplasm often involves 
      its invasion into and destruction of the extracellular matrix. We examined 
      neoplastic cysts of ovarian mucinous tumors for the presence of matrix 
      metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) using zymography 
      (in situ zymography, gelatin zymography, and casein zymography) and enzyme-linked 
      immunosorbent assay. RESULTS: Matriolytic activity was detected within the cystic 
      contents and cytoplasm of the lining epithelial cells of the cyst by in situ 
      zymography. This intracystic matriolytic activity was thought to originate mainly 
      in the epithelial cells. The activated form of MMP-9 was seen in all carcinoma 
      and borderline fluids and in 7 of 15 adenomas. The concentration of MMP-9 was 
      higher in carcinoma fluids than in borderline and adenoma fluids (P < 0.05). 
      TIMP-1, which specifically binds to MMP-9, was also higher in carcinoma and 
      borderline fluids than in adenoma fluids (P < 0.05). MMP-2 activity was nearly 
      ubiquitously present in all cyst fluids, irrespective of the fluid's histologic 
      category. The amount of MMP-2 was highest in the carcinoma category, although not 
      to a statistically significant degree. TIMP-2, a specific inhibitor for MMP-2, 
      was significantly lower in the borderline category than in the adenoma category. 
      The molar ratios of TIMP-1/MMP-9 (not significant) and TIMP-2/MMP-2 (P < 0.05) 
      were higher in the adenoma category. Expressions of trypsin, MMP-7, and MMP-9 
      were generally higher in carcinoma and borderline fluids than in adenoma fluids. 
      CONCLUSIONS: These observations indicate the importance of ovarian cystic fluids 
      for analyzing tumor-associated matriolytic activities. The findings suggest that 
      these matriolytic enzymes, together with the presence of their inhibitors, play 
      an important role in the growth of ovarian mucinous tumors.
CI  - Copyright 2000 Academic Press.
FAU - Furuya, M
AU  - Furuya M
AD  - Department of Pathology, Hokkaido University School of Medicine, Sapporo, Japan.
FAU - Ishikura, H
AU  - Ishikura H
FAU - Kawarada, Y
AU  - Kawarada Y
FAU - Ogawa, Y
AU  - Ogawa Y
FAU - Sakuragi, N
AU  - Sakuragi N
FAU - Fujimoto, S
AU  - Fujimoto S
FAU - Yoshiki, T
AU  - Yoshiki T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 9000-70-8 (Gelatin)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adenocarcinoma, Mucinous/enzymology/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cyst Fluid/*enzymology/metabolism
MH  - Cystadenocarcinoma, Mucinous/enzymology/metabolism/pathology
MH  - Cystadenoma, Mucinous/enzymology/metabolism/pathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epithelium/enzymology/metabolism/pathology
MH  - Female
MH  - Gelatin/metabolism
MH  - Humans
MH  - Matrix Metalloproteinase 2/biosynthesis/*metabolism
MH  - Matrix Metalloproteinase 9/biosynthesis/*metabolism
MH  - Middle Aged
MH  - Ovarian Neoplasms/*enzymology/metabolism/pathology
MH  - Tissue Inhibitor of Metalloproteinase-1/biosynthesis/*metabolism
MH  - Tissue Inhibitor of Metalloproteinase-2/biosynthesis/*metabolism
EDAT- 2000/08/06 11:00
MHDA- 2000/09/02 11:01
CRDT- 2000/08/06 11:00
PHST- 2000/08/06 11:00 [pubmed]
PHST- 2000/09/02 11:01 [medline]
PHST- 2000/08/06 11:00 [entrez]
AID - S0090-8258(00)95856-6 [pii]
AID - 10.1006/gyno.2000.5856 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2000 Aug;78(2):106-12. doi: 10.1006/gyno.2000.5856.